What is ClearPoint Neuro, Inc.'s earnings per share (EPS)?

ClearPoint Neuro, Inc. (CLPT) reported diluted earnings per share of -$0.90 for fiscal year 2025. This represents a -28.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ClearPoint Neuro, Inc. (CLPT) Financials

CLPT

Trailing 12 months to June 30, 2026

Revenue $42.3M +25.9% YoY

Net Income -$34.6M -55.5% YoY

EPS (Diluted) -$1.18 -45.7% YoY

Free Cash Flow -$31.3M -166.9% YoY

Market Cap $299.2M as of Oct 13, 2026

Price / Sales 7.1x on $42.3M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 27.8x on $10.8M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 3, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLPT SEC filings page.

ClearPoint Neuro, Inc. (CLPT) reported $42.3M in revenue over the twelve months to Jun 30, 2026, up 25.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLPT FY2025 2026-10-03

Revenue is scaling, but higher operating costs and new debt have made losses and cash needs widen sharply.

In FY2025, the net loss of $25.5M nearly matched operating cash flow of -$23.9M, so reported losses were translating into cash needs rather than remaining largely non-cash. Free cash flow of -$24.4M alongside only $522K of capital spending indicates the gap is driven mainly by ongoing operations, not a heavy reinvestment program.

The business has improved gross margin from 56.8% in FY2023 to 61.4% in FY2025, but operating margin remained deeply negative. SG&A and R&D together reached $30.4M in FY2025, absorbing the benefit of that margin improvement before it reached operating profit.

Financing changed the balance-sheet posture: debt-to-equity rose from 0.5x in FY2024 to 1.8x in FY2025, indicating greater reliance on creditors. Yet a 5.9x current ratio and 23.1 months of reported outflow comparison show short-term resources remain distinct from the company's heavier long-term obligations.

Financial Health Signals

Financial Health Score 50/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of ClearPoint Neuro, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

ClearPoint Neuro, Inc. held $45.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $23.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and ClearPoint Neuro, Inc. scores 48/100 among other emerging companies.

Dilution

ClearPoint Neuro, Inc. had 30M shares outstanding at the end of fiscal year 2025, against 28M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and ClearPoint Neuro, Inc. scores 58/100 among other emerging companies.

R&D Intensity

ClearPoint Neuro, Inc. spent $13.9M on research and development in fiscal year 2025, which was 22.7% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and ClearPoint Neuro, Inc. scores 55/100 among other emerging companies.

Revenue Progress

ClearPoint Neuro, Inc. reported revenue of $37.0M in fiscal year 2025, against $31.4M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and ClearPoint Neuro, Inc. scores 68/100 among other emerging companies.

Burn Trend

ClearPoint Neuro, Inc.'s operations used $23.9M of cash in fiscal year 2025, against $8.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and ClearPoint Neuro, Inc. scores 22/100 among other emerging companies.

Balance Sheet

ClearPoint Neuro, Inc.'s cash, cash equivalents and investments came to $45.9M at the end of fiscal year 2025, against $69.7M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and ClearPoint Neuro, Inc. scores 49/100 among other emerging companies.

Altman Z-Score Distress

-0.32

ClearPoint Neuro, Inc. scores -0.32, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($299.2M) relative to total liabilities ($69.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

ClearPoint Neuro, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

ClearPoint Neuro, Inc. reported a net loss of $25.5M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

ClearPoint Neuro, Inc. reported an operating loss of $24.2M against $2.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$10.9M

YoY+18.1%

QoQ-10.3%

5Y CAGR+26.1%

10Y CAGR+25.7%

ClearPoint Neuro, Inc. generated $10.9M in revenue in Q2 2026. This represents an increase of 18.1% from the same quarter a year earlier. Against the prior quarter it is down 10.3%.

EBITDA

-$10.1M

YoY-91.0%

QoQ-20.3%

ClearPoint Neuro, Inc.'s EBITDA was -$10.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 91.0% from the same quarter a year earlier. Against the prior quarter it is down 20.3%.

Net Income

-$11.3M

YoY-94.2%

QoQ-18.7%

ClearPoint Neuro, Inc. reported -$11.3M in net income in Q2 2026. This represents a decrease of 94.2% from the same quarter a year earlier. Against the prior quarter it is down 18.7%.

EPS (Diluted)

-$0.38

YoY-81.0%

QoQ-18.8%

ClearPoint Neuro, Inc. earned -$0.38 per diluted share (EPS) in Q2 2026. This represents a decrease of 81.0% from the same quarter a year earlier. Against the prior quarter it is down 18.8%.

Cash & Balance Sheet

Free Cash Flow

-$7.2M

YoY-173.5%

QoQ+16.1%

ClearPoint Neuro, Inc. recorded an outflow of $7.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 173.5% from the same quarter a year earlier. Against the prior quarter it is up 16.1%.

Cash & Debt

$29.4M

YoY-29.3%

QoQ-17.5%

5Y CAGR-13.8%

10Y CAGR+30.7%

ClearPoint Neuro, Inc. held $29.4M in cash against $50.2M in long-term debt as of Q2 2026.

Shares Outstanding

31M

YoY+7.3%

QoQ+1.7%

5Y CAGR+6.4%

10Y CAGR+28.9%

ClearPoint Neuro, Inc. had 31M shares outstanding in Q2 2026. This represents an increase of 7.3% from the same quarter a year earlier. Against the prior quarter it is up 1.7%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

61.7%

YoY+1.4pp

QoQ-2.3pp

5Y change-5.0pp

10Y change+8.9pp

ClearPoint Neuro, Inc.'s gross margin was 61.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.3 percentage points.

Operating Margin

-94.2%

YoY-32.5pp

QoQ-24.3pp

5Y change+5.7pp

ClearPoint Neuro, Inc.'s operating margin was -94.2% in Q2 2026, reflecting core business profitability. This is down 32.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 24.3 percentage points.

Return on Equity

-105.2%

YoY-75.7pp

QoQ-54.5pp

5Y change-97.4pp

ClearPoint Neuro, Inc.'s ROE was -105.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 75.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 54.5 percentage points.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$4.6M

YoY+21.0%

QoQ+2.4%

5Y CAGR+17.0%

10Y CAGR+20.0%

ClearPoint Neuro, Inc. invested $4.6M in research and development in Q2 2026. This represents an increase of 21.0% from the same quarter a year earlier. Against the prior quarter it is up 2.4%.

Capital Expenditures

$214K

YoY+135.2%

QoQ-66.8%

5Y CAGR+43.6%

ClearPoint Neuro, Inc. invested $214K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 135.2% from the same quarter a year earlier. Against the prior quarter it is down 66.8%.

Share Buybacks

Not reported for Q2 2026.

CLPT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLPT quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$42.3M	$37.0M+17.8%	$31.4M+31.0%	$24.0M+16.6%	$20.6M+26.1%	$16.3M+27.0%	$12.8M+14.4%	$11.2M+52.5%	$7.4M-0.4%	$7.4M+28.4%	$5.7M+25.1%	$4.6M+27.5%	$3.6M-8.3%	$3.9M-22.3%	$5.1M+32.5%	$3.8M
Cost of Revenue	$15.8M	$14.3M+16.4%	$12.3M+18.6%	$10.3M+47.3%	$7.0M+35.6%	$5.2M+39.6%	$3.7M-5.9%	$3.9M+62.0%	$2.4M-16.1%	$2.9M+9.7%	$2.6M+33.0%	$2.0M+3.1%	$1.9M+35.6%	$1.4M+155.7%	$556K-15.3%	$656K
Gross Profit	$26.5M	$22.7M+18.7%	$19.1M+40.5%	$13.6M+0.6%	$13.5M+21.6%	$11.1M+22.0%	$9.1M+25.4%	$7.3M+47.9%	$4.9M+9.8%	$4.5M+44.2%	$3.1M+19.2%	$2.6M+55.4%	$1.7M-33.2%	$2.5M-44.3%	$4.5M+42.4%	$3.2M
R&D Expenses	$15.8M	$13.9M+12.1%	$12.4M+5.8%	$11.7M+7.5%	$10.9M+17.4%	$9.3M+98.1%	$4.7M+66.8%	$2.8M+21.6%	$2.3M-17.9%	$2.8M+7.1%	$2.6M+34.3%	$2.0M-40.6%	$3.3M+12.8%	$2.9M+17.6%	$2.5M-41.6%	$4.3M
SG&A Expenses	$19.6M	$16.5M+37.6%	$12.0M+2.0%	$11.8M+22.3%	$9.6M+20.2%	$8.0M+51.8%	$5.3M+22.5%	$4.3M-0.5%	$4.3M+6.9%	$4.0M-3.4%	$4.2M-49.9%	$8.4M+4.1%	$8.0M+13.9%	$7.1M+17.1%	$6.0M+24.8%	$4.8M
Operating Income	-$31.0M	-$24.2M-22.4%	-$19.7M+12.1%	-$22.4M-37.4%	-$16.3M-22.1%	-$13.4M-115.0%	-$6.2M-35.4%	-$4.6M+12.5%	-$5.2M+17.2%	-$6.3M+15.4%	-$7.5M+16.6%	-$9.0M-68.7%	-$5.3M+28.8%	-$7.5M-138.9%	-$3.1M+47.2%	-$5.9M
EBITDA	N/A	-$23.4M-24.5%	-$18.8M+14.1%	-$21.8M-35.6%	-$16.1M-21.7%	-$13.2M-124.5%	-$5.9M-32.3%	-$4.5M+13.4%	-$5.1M+17.4%	-$6.2M+15.2%	-$7.3M+16.3%	-$8.8M-77.3%	-$4.9M+29.9%	-$7.0M-159.9%	-$2.7M+51.3%	-$5.6M
Interest Expense	$4.8M	$2.4M+361.0%	$518K+34.2%	$386K+376.5%	$81K-91.7%	$973K-32.6%	$1.4M+51.2%	$955K-2.6%	$980K+12.3%	$873K-17.0%	$1.1M-16.7%	$1.3M+23.9%	$1.0M+103.8%	$500K-80.7%	$2.6M+3.9%	$2.5M
Income Tax	-$18K	$55K+358.3%	$12K+50.0%	$8K	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	N/A
Net Income	-$34.6M	-$25.5M-35.0%	-$18.9M+14.4%	-$22.1M-34.4%	-$16.4M-14.1%	-$14.4M-112.5%	-$6.8M-22.4%	-$5.5M+10.1%	-$6.2M+14.0%	-$7.2M+11.2%	-$8.1M+4.5%	-$8.4M-86.7%	-$4.5M+36.1%	-$7.1M-20.6%	-$5.9M+29.3%	-$8.3M
EPS (Basic)	N/A	-$0.90-28.6%	-$0.70+22.2%	-$0.90-32.4%	-$0.68+1.4%	-$0.69	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.18	-$0.90-28.6%	-$0.70+22.2%	-$0.90-32.4%	-$0.68+1.4%	-$0.69	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	28M+4.8%	27M+9.8%	25M+1.8%	24M+16.6%	21M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$10.9M+18.1%	$12.1M+42.9%	$10.4M+34.0%	$8.9M+9.1%	$9.2M+17.3%	$8.5M+11.1%	$7.8M+14.1%	$8.1M+41.0%
Cost of Revenue	$4.2M+14.0%	$4.4M+30.4%	$4.0M+33.1%	$3.3M-0.4%	$3.7M+27.5%	$3.4M+7.7%	$3.0M+7.6%	$3.3M+31.6%
Gross Profit	$6.7M+20.8%	$7.8M+51.1%	$6.4M+34.5%	$5.6M+15.5%	$5.6M+11.4%	$5.1M+13.4%	$4.8M+18.7%	$4.8M+48.1%
R&D Expenses	$4.6M+21.0%	$4.5M+33.8%	$3.2M-2.9%	$3.5M+4.1%	$3.8M+22.7%	$3.4M+28.7%	$3.3M+25.6%	$3.3M+36.5%
SG&A Expenses	$5.6M+63.9%	$5.0M+22.4%	$5.4M+66.9%	$3.6M+14.2%	$3.4M+22.8%	$4.1M+44.4%	$3.3M+19.9%	$3.1M+8.3%
Operating Income	-$10.2M-80.4%	-$8.5M-37.6%	-$7.0M-25.0%	-$5.3M-2.3%	-$5.7M-20.2%	-$6.2M-46.2%	-$5.6M-19.8%	-$5.2M-5.3%
EBITDA	-$10.1M-91.0%	-$8.4M-38.5%	-$6.8M-25.9%	-$5.2M-6.5%	-$5.3M-17.7%	-$6.1M-52.5%	-$5.4M-19.3%	-$4.9M-3.3%
Interest Expense	$1.4M+287.1%	$1.4M	$2.6M+2104.7%	-$543K-359.8%	$365K+12.0%	$0-100.0%	-$128K-240.7%	$209K+109.0%
Income Tax	-$38K-252.0%	$8K-55.6%	$4K+112.5%	$8K-42.9%	$25K+66.7%	$18K+20.0%	-$32K	$14K
Net Income	-$11.3M-94.2%	-$9.6M-58.5%	-$7.8M-44.6%	-$5.9M-18.4%	-$5.8M-32.4%	-$6.0M-45.3%	-$5.4M-16.6%	-$5.0M-3.4%
EPS (Basic)	-$0.38-81.0%	-$0.32-45.5%	-$0.27-35.0%	-$0.21-16.7%	-$0.21-31.2%	-$0.22-37.5%	-$0.20-5.3%	-$0.18+10.0%
EPS (Diluted)	-$0.38-81.0%	-$0.32-45.5%	-$0.27-35.0%	-$0.21-16.7%	-$0.21-31.2%	-$0.22-37.5%	-$0.20-5.3%	-$0.18+10.0%
Diluted Shares (Avg)	30M+6.8%	30M+6.6%	N/A	28M+3.0%	28M+2.9%	28M+8.9%	N/A	28M+12.0%

CLPT Balance Sheet

CLPT quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$97.7M+149.4%	$39.2M-8.1%	$42.7M-23.1%	$55.5M-15.4%	$65.6M+122.2%	$29.5M+147.5%	$11.9M+51.8%	$7.9M-43.5%	$13.9M+87.8%	$7.4M-25.5%	$9.9M-25.8%	$13.4M+70.0%	$7.9M+41.8%	$5.6M+83.2%	$3.0M
Current Assets	$63.6M+90.6%	$33.4M-7.8%	$36.2M-29.3%	$51.2M-17.3%	$61.9M+143.1%	$25.5M+145.2%	$10.4M+56.0%	$6.7M-47.8%	$12.7M+109.5%	$6.1M-28.7%	$8.5M-27.1%	$11.7M+97.1%	$5.9M+93.1%	$3.1M+100.3%	$1.5M
Cash & Equivalents	$45.9M+128.4%	$20.1M-13.1%	$23.1M-16.2%	$27.6M-49.0%	$54.1M+169.2%	$20.1M+252.9%	$5.7M+83.7%	$3.1M-66.6%	$9.3M+180.2%	$3.3M-38.7%	$5.4M-41.5%	$9.2M+162.9%	$3.5M+117.1%	$1.6M+1013.6%	$145K
Short-Term Investments	$0	$0	$0-100.0%	$9.9M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$8.4M+21.8%	$6.9M-13.2%	$7.9M-15.0%	$9.3M+88.4%	$4.9M+52.5%	$3.2M-0.1%	$3.2M+53.8%	$2.1M-9.0%	$2.3M+30.9%	$1.8M-2.2%	$1.8M-8.0%	$2.0M+33.0%	$1.5M+64.2%	$900K-7.1%	$969K
Accounts Receivable	$6.5M+39.0%	$4.7M+46.8%	$3.2M+20.5%	$2.7M+14.0%	$2.3M+24.2%	$1.9M+72.6%	$1.1M-11.7%	$1.2M+30.0%	$949K+9.6%	$866K-28.9%	$1.2M+159.7%	$469K-39.1%	$770K+72.9%	$445K+10.9%	$402K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$7.5M0.0%	$7.5M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$69.7M+405.3%	$13.8M-35.8%	$21.5M+15.5%	$18.6M+10.8%	$16.8M-38.1%	$27.1M+269.7%	$7.3M+15.7%	$6.3M-21.4%	$8.1M-1.1%	$8.2M-31.6%	$11.9M-11.6%	$13.5M-8.3%	$14.7M+9.6%	$13.4M-46.1%	$24.9M
Current Liabilities	$10.8M+4.0%	$10.4M+39.3%	$7.4M+9.5%	$6.8M+42.8%	$4.8M+48.5%	$3.2M-16.5%	$3.8M+105.2%	$1.9M-57.5%	$4.4M+45.7%	$3.0M-60.6%	$7.7M+55.6%	$4.9M-51.2%	$10.1M+60.0%	$6.3M-56.8%	$14.6M
Non-Current Liabilities	$59.0M+1610.5%	$3.4M-75.5%	$14.1M+19.0%	$11.8M-1.9%	$12.0M-49.7%	$23.9M+582.5%	$3.5M-21.7%	$4.5M+22.0%	$3.7M-28.6%	$5.1M+20.5%	$4.3M-50.2%	$8.6M+85.6%	$4.6M-35.1%	$7.1M-30.9%	$10.3M
Long-Term Debt	$49.1M	N/A	$9.9M+0.6%	$9.9M+0.6%	$9.8M-53.8%	$21.3M+926.7%	$2.1M-40.5%	$3.5M-29.2%	$4.9M+9.5%	$4.5M-44.6%	$8.1M-26.3%	$11.0M	N/A	N/A	N/A
Total Equity	$28.0M+10.4%	$25.4M+19.9%	$21.2M-42.6%	$36.9M-24.4%	$48.8M+1952.5%	$2.4M-48.2%	$4.6M+203.7%	$1.5M-74.1%	$5.8M+870.9%	-$756K+61.8%	-$2.0M-1874.6%	-$100K+98.5%	-$6.8M+13.1%	-$7.9M+64.0%	-$21.8M
Retained Earnings	-$216.9M-13.3%	-$191.4M-11.0%	-$172.5M-14.7%	-$150.4M-12.3%	-$133.9M-12.1%	-$119.5M-6.0%	-$112.7M-5.2%	-$107.2M-6.1%	-$101.0M-7.6%	-$93.9M-9.5%	-$85.7M-10.9%	-$77.3M-6.2%	-$72.8M-10.8%	-$65.7M-9.8%	-$59.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$86.7M+38.0%	$93.4M+210.7%	$97.7M+149.4%	$60.4M+50.2%	$62.9M+19.6%	$30.1M-43.9%	$39.2M-8.1%	$40.2M-8.3%
Current Assets	$48.9M-9.4%	$54.9M+126.6%	$63.6M+90.6%	$51.3M+49.5%	$54.0M+16.0%	$24.2M-49.1%	$33.4M-7.8%	$34.3M-8.0%
Cash & Equivalents	$29.4M-29.3%	$35.6M+187.3%	$45.9M+128.4%	$38.2M+77.2%	$41.5M+26.5%	$12.4M-65.0%	$20.1M-13.1%	$21.6M-11.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$8.8M+40.0%	$8.6M+30.2%	$8.4M+21.8%	$6.6M-6.7%	$6.3M-21.6%	$6.6M-17.3%	$6.9M-13.2%	$7.1M-21.5%
Accounts Receivable	$8.4M+97.1%	$8.7M+137.3%	$6.5M+39.0%	$4.0M+3.2%	$4.3M+22.6%	$3.7M+45.4%	$4.7M+46.8%	$3.9M+59.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$7.5M	$7.5M	$7.5M0.0%	N/A	N/A	N/A	$7.5M	N/A
Total Liabilities	$76.0M+76.1%	$74.6M+639.6%	$69.7M+405.3%	$44.5M+297.5%	$43.1M+111.0%	$10.1M-47.1%	$13.8M-35.8%	$11.2M-43.3%
Current Liabilities	$10.3M+39.4%	$9.5M+38.1%	$10.8M+4.0%	$8.1M+6.6%	$7.4M-55.7%	$6.9M-54.7%	$10.4M+39.3%	$7.6M+35.2%
Non-Current Liabilities	$65.7M+83.8%	$65.1M+1923.5%	$59.0M+1610.5%	$36.4M+901.4%	$35.7M+853.3%	$3.2M-17.4%	$3.4M-75.5%	$3.6M-74.3%
Long-Term Debt	$50.2M+74.1%	$49.6M	$49.1M	$29.2M	$28.8M+189.1%	N/A	N/A	N/A
Total Equity	$10.8M-45.4%	$18.8M-5.7%	$28.0M+10.4%	$15.9M-45.3%	$19.7M-38.6%	$20.0M-42.2%	$25.4M+19.9%	$29.0M+20.4%
Retained Earnings	-$237.8M-17.0%	-$226.5M-14.7%	-$216.9M-13.3%	-$209.1M-12.4%	-$203.2M-12.3%	-$197.4M-11.8%	-$191.4M-11.0%	-$186.0M-10.8%

CLPT Cash Flow Statement

CLPT quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$30.2M	-$23.9M-167.0%	-$8.9M+34.8%	-$13.7M+15.1%	-$16.2M-27.3%	-$12.7M-62.6%	-$7.8M-173.9%	-$2.9M+38.5%	-$4.6M+22.7%	-$6.0M-3.0%	-$5.8M+32.6%	-$8.6M-19.1%	-$7.3M+6.8%	-$7.8M-4.6%	-$7.4M-19.1%	-$6.2M
Depreciation & Amortization	N/A	$814K-16.9%	$980K+56.5%	$626K+156.6%	$244K+53.5%	$159K-52.4%	$334K+131.9%	$144K+31.6%	$109K-6.0%	$116K-25.2%	$156K-26.5%	$212K-43.8%	$377K-11.5%	$426K+2.2%	$417K+17.5%	$355K
Stock-Based Compensation	N/A	$8.2M+18.4%	$6.9M+13.6%	$6.1M+47.3%	$4.1M+98.6%	$2.1M+90.6%	$1.1M+36.4%	$799K-35.1%	$1.2M-1.1%	$1.2M+4.9%	$1.2M-29.4%	$1.7M+91.0%	$881K-39.6%	$1.5M-28.2%	$2.0M+105.2%	$990K
Capital Expenditures	$1.1M	$522K+89.8%	$275K-61.6%	$717K+183.4%	$253K+50.6%	$168K+309.8%	$41K+310.0%	$10K-84.2%	$63K+137.3%	$27K-73.5%	$101K+31.4%	$77K+59.7%	$48K-35.4%	$74K-41.6%	$127K+388.3%	$26K
Free Cash Flow	-$31.3M	-$24.4M-164.7%	-$9.2M+36.1%	-$14.4M+12.1%	-$16.4M-27.6%	-$12.9M-63.9%	-$7.8M-174.4%	-$2.9M+39.1%	-$4.7M+22.0%	-$6.0M-1.7%	-$5.9M+32.1%	-$8.7M-19.4%	-$7.3M+7.1%	-$7.9M-3.9%	-$7.6M-20.7%	-$6.3M
Investing Cash Flow	$30K	$615K+323.6%	-$275K-103.1%	$8.9M+183.4%	-$10.7M-6290.5%	-$168K+65.1%	-$482K-201.3%	-$160K-152.0%	-$63K-137.3%	-$27K+73.5%	-$101K	N/A	-$48K+72.4%	-$174K-36.9%	-$127K-388.3%	-$26K
Financing Cash Flow	$18.7M	$50.2M+710.8%	$6.2M+1990.9%	$296K-27.6%	$409K-99.1%	$46.9M+106.6%	$22.7M+304.9%	$5.6M+475.0%	-$1.5M-112.5%	$12.0M+213.3%	$3.8M	N/A	$13.0M+32.3%	$9.8M+9.0%	$9.0M+86.9%	$4.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$7.0M-174.9%	-$8.0M-29.1%	-$12.1M-869.8%	-$3.1M-160.3%	-$2.6M+4.3%	-$6.2M-60.7%	-$1.2M-6.3%	-$1.2M+33.2%
Depreciation & Amortization	$150K-62.1%	$86K-16.5%	$249K+3.8%	$66K-75.0%	$396K+70.0%	$103K-57.6%	$240K+31.1%	$264K+67.1%
Stock-Based Compensation	$2.3M+0.1%	$2.2M+16.2%	N/A	$2.0M+6.2%	$2.3M+26.3%	$1.9M+26.9%	N/A	$1.9M+20.2%
Capital Expenditures	$214K+135.2%	$645K+252.5%	$49K-81.4%	$199K+1558.3%	$91K	$183K	$263K+1152.4%	$12K-94.9%
Free Cash Flow	-$7.2M-173.5%	-$8.6M-35.5%	-$12.1M-703.7%	-$3.3M-174.2%	-$2.6M+0.9%	-$6.4M-65.5%	-$1.5M-26.6%	-$1.2M+40.4%
Investing Cash Flow	-$214K-135.2%	-$645K-252.5%	$1.1M+513.7%	-$199K-1558.3%	-$91K	-$183K	-$263K-39.9%	-$12K+94.9%
Financing Cash Flow	$1.0M-96.9%	-$1.8M-35.5%	$19.6M+52775.7%	$0+100.0%	$32.0M+19885.6%	-$1.4M-108.5%	$37K-76.1%	-$10.1M-10956.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CLPT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLPT quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	61.4%+0.5pp	60.9%+4.1pp	56.8%-9.0pp	65.8%-2.4pp	68.2%-2.8pp	71.1%+6.2pp	64.9%-2.1pp	66.9%+6.2pp	60.7%+6.7pp	54.0%-2.7pp	56.7%+10.2pp	46.5%-17.3pp	63.8%-25.2pp	89.0%+6.2pp	82.8%
Operating Margin	-65.4%-2.5pp	-62.9%+30.8pp	-93.7%-14.2pp	-79.5%+2.6pp	-82.0%-33.6pp	-48.5%-7.5pp	-41.0%+30.4pp	-71.4%+14.5pp	-85.9%	-130.3%	-195.3%	-147.6%	-190.2%	-61.9%	-155.1%
Net Margin	-69.1%-8.8pp	-60.3%+32.0pp	-92.2%-12.2pp	-80.0%+8.4pp	-88.4%-35.6pp	-52.9%-3.5pp	-49.4%+34.4pp	-83.8%+13.3pp	-97.1%	-140.4%	-183.9%	-125.5%	-180.3%	-116.2%	-217.7%
Return on Equity	-91.1%-16.6pp	-74.5%+29.8pp	-104.3%-59.8pp	-44.5%-15.0pp	-29.5%+255.8pp	-285.3%-164.5pp	-120.8%+287.4pp	-408.2%-285.2pp	-123.0%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-26.1%+22.1pp	-48.3%+3.5pp	-51.8%-22.2pp	-29.6%-7.7pp	-22.0%+1.0pp	-23.0%+23.5pp	-46.5%+32.0pp	-78.5%-26.9pp	-51.6%+57.5pp	-109.0%-24.0pp	-85.0%-51.2pp	-33.8%+56.2pp	-90.0%+15.9pp	-105.9%+168.4pp	-274.3%
Current Ratio	5.91+2.7x	3.22-1.6x	4.87-2.7x	7.54-5.5x	13.02+5.1x	7.96+5.2x	2.71-0.9x	3.56+0.7x	2.90+0.9x	2.02+0.9x	1.11-1.3x	2.38+1.8x	0.59+0.1x	0.49+0.4x	0.11
Debt-to-Equity	1.75+1.2x	0.54+0.1x	0.47+0.2x	0.27+0.1x	0.20-8.8x	8.95+8.5x	0.45-1.9x	2.31+1.5x	0.84	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.38-0.4x	0.80+0.2x	0.56+0.2x	0.37+0.1x	0.25-0.2x	0.43-0.5x	0.940.0x	0.94+0.4x	0.53-0.2x	0.78+0.3x	0.46+0.2x	0.27-0.2x	0.50-0.4x	0.91-0.3x	1.26
FCF Margin	-66.1%-36.7pp	-29.4%+30.9pp	-60.3%+19.6pp	-79.9%-1.0pp	-78.9%-17.8pp	-61.2%-35.7pp	-25.5%+38.3pp	-63.8%+17.7pp	-81.6%	-103.0%	-189.7%	-202.5%	-199.8%	-149.5%	-164.1%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	61.7%+1.4pp	63.9%+3.5pp	61.5%+0.2pp	63.2%+3.5pp	60.3%-3.2pp	60.5%+1.2pp	61.3%+2.3pp	59.7%+2.9pp
Operating Margin	-94.2%-32.5pp	-69.9%+2.7pp	-67.7%+4.8pp	-59.5%+4.0pp	-61.6%-1.5pp	-72.6%-17.4pp	-72.5%-3.4pp	-63.5%+21.5pp
Net Margin	-104.2%	-78.8%-7.7pp	-74.8%-5.5pp	-66.5%-5.2pp	-63.3%-7.2pp	-71.0%-16.8pp	-69.3%-1.5pp	-61.2%+22.2pp
Return on Equity	-105.2%-75.7pp	-50.7%-20.6pp	-27.8%-6.6pp	-37.1%-20.0pp	-29.6%-15.8pp	-30.1%-18.2pp	-21.2%+0.6pp	-17.2%+2.8pp
Return on Assets	-13.1%-3.8pp	-10.2%+9.8pp	-8.0%+5.8pp	-9.8%+2.6pp	-9.3%-0.9pp	-20.0%-12.3pp	-13.7%-2.9pp	-12.4%-1.4pp
Current Ratio	4.74-2.6x	5.79+2.3x	5.91+2.7x	6.37+1.8x	7.30+4.5x	3.53+0.4x	3.22-1.6x	4.54-2.1x
Debt-to-Equity	4.66+3.2x	2.63+2.1x	1.75+1.2x	1.84+1.5x	1.46+1.2x	0.50+0.2x	0.54+0.1x	0.390.0x
Asset Turnover	0.130.0x	0.13-0.2x	0.11-0.1x	0.15-0.1x	0.150.0x	0.28+0.1x	0.200.0x	0.20+0.1x
FCF Margin	-66.4%-37.8pp	-71.0%+3.9pp	-116.3%	-37.5%-22.6pp	-28.7%+5.3pp	-74.9%-24.6pp	-19.4%-1.9pp	-14.9%+20.3pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
ClearPoint Neuro, Inc. CLPT	FY2025	$37.0M	-$25.5M	-69.1%	$299.2M	50/100
SANUWAVE Health, Inc. SNWV	FY2025	$44.1M	$11.8M	26.8%	$50.2M	69/100
Tactile Systems Technology, Inc. TCMD	FY2025	$329.5M	$19.1M	5.8%	$512.4M	71/100
Neuropace, Inc. NPCE	FY2025	$100.0M	-$21.5M	-21.5%	$446.2M	61/100
Butterfly Network, Inc. BFLY	FY2025	$97.6M	-$77.1M	-79.0%	$2.3B	61/100
RxSight, Inc. RXST	FY2025	$134.5M	-$39	0.0%	$193.8M	73/100

Where ClearPoint Neuro, Inc. Ranks

Frequently Asked Questions

What is ClearPoint Neuro, Inc.'s annual revenue?

ClearPoint Neuro, Inc. (CLPT) reported $37.0M in total revenue for fiscal year 2025. This represents a 17.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is ClearPoint Neuro, Inc.'s revenue growing?

ClearPoint Neuro, Inc. (CLPT) revenue grew by 17.8% year-over-year, from $31.4M to $37.0M in fiscal year 2025.

Is ClearPoint Neuro, Inc. profitable?

No, ClearPoint Neuro, Inc. (CLPT) reported a net income of -$25.5M in fiscal year 2025, with a net profit margin of -69.1%.

What is ClearPoint Neuro, Inc.'s EBITDA?

ClearPoint Neuro, Inc. (CLPT) had EBITDA of -$23.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does ClearPoint Neuro, Inc. have?

As of fiscal year 2025, ClearPoint Neuro, Inc. (CLPT) had $45.9M in cash and equivalents against $49.1M in long-term debt.

What is ClearPoint Neuro, Inc.'s gross margin?

ClearPoint Neuro, Inc. (CLPT) had a gross margin of 61.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is ClearPoint Neuro, Inc.'s operating margin?

ClearPoint Neuro, Inc. (CLPT) had an operating margin of -65.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is ClearPoint Neuro, Inc.'s net profit margin?

ClearPoint Neuro, Inc. (CLPT) had a net profit margin of -69.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is ClearPoint Neuro, Inc.'s return on equity (ROE)?

ClearPoint Neuro, Inc. (CLPT) has a return on equity of -91.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is ClearPoint Neuro, Inc.'s free cash flow?

ClearPoint Neuro, Inc. (CLPT) recorded an outflow of $24.4M in free cash flow during fiscal year 2025. This represents a -164.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is ClearPoint Neuro, Inc.'s operating cash flow?

ClearPoint Neuro, Inc. (CLPT) recorded an outflow of $23.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are ClearPoint Neuro, Inc.'s total assets?

ClearPoint Neuro, Inc. (CLPT) had $97.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are ClearPoint Neuro, Inc.'s capital expenditures?

ClearPoint Neuro, Inc. (CLPT) invested $522K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does ClearPoint Neuro, Inc. spend on research and development?

ClearPoint Neuro, Inc. (CLPT) invested $13.9M in research and development during fiscal year 2025.

How many shares does ClearPoint Neuro, Inc. have outstanding?

ClearPoint Neuro, Inc. (CLPT) had 30M shares outstanding as of fiscal year 2025.

What is ClearPoint Neuro, Inc.'s current ratio?

ClearPoint Neuro, Inc. (CLPT) had a current ratio of 5.91 as of fiscal year 2025, which is generally considered healthy.

What is ClearPoint Neuro, Inc.'s debt-to-equity ratio?

ClearPoint Neuro, Inc. (CLPT) had a debt-to-equity ratio of 1.75 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is ClearPoint Neuro, Inc.'s return on assets (ROA)?

ClearPoint Neuro, Inc. (CLPT) had a return on assets of -26.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is ClearPoint Neuro, Inc.'s P/E ratio?

ClearPoint Neuro, Inc. (CLPT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $299.2M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is ClearPoint Neuro, Inc.'s price-to-sales ratio?

ClearPoint Neuro, Inc. (CLPT) trades at 7.1x sales, its market capitalization divided by revenue of $42.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $299.2M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does ClearPoint Neuro, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, ClearPoint Neuro, Inc. (CLPT) held $45.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.9M over that year. Dividing the one by the other, the reported balance equals about 23 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is ClearPoint Neuro, Inc.'s Altman Z-Score?

ClearPoint Neuro, Inc. (CLPT) has an Altman Z-Score of -0.32, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is ClearPoint Neuro, Inc.'s Piotroski F-Score?

ClearPoint Neuro, Inc. (CLPT) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are ClearPoint Neuro, Inc.'s earnings high quality?

ClearPoint Neuro, Inc. (CLPT) reported a net loss of $25.5M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can ClearPoint Neuro, Inc. cover its interest payments?

ClearPoint Neuro, Inc. (CLPT) reported an operating loss of $24.2M against $2.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is ClearPoint Neuro, Inc.?

ClearPoint Neuro, Inc. (CLPT) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.